Skip to main content

Advertisement

Table 5 Correlation between FGFR1 gene amplification and the clinicopathological variables in the oestrogen-receptor-positive group

From: FGFR1 amplification in breast carcinomas: a chromogenic in situhybridisation analysis

Parameter Number of samples Positive FGFR1 amplification number (%) P value
Age 313   Not significant
   <50 years 95 6 (6.3)  
   ≥50 years 218 21 (9.6)  
Grade 313   Not significant
   1 99 8 (8.1)  
   2 120 10 (8.3)  
   3 94 9 (9.6)  
Size 313   Not significant
   ≥1.5 cm 188 19 (10.1)  
   <1.5 cm 125 8 (6.4)  
Lymph node stage 311   Not significant
   N0 214 19 (8.9)  
   N1 74 6 (8.2)  
   N2 23 2 (9.3)  
Nottingham Prognostic Index 311   Not significant
   Good 148 11 (7.4)  
   Moderate 133 14 (10.5)  
   Poor 30 2 (6.7)  
Distant metastasis 313   0.032
   No 273 20 (7.3)  
   Definite 40 7 (17.5)  
Vascular invasion 303   Not significant
   No 224 18 (8)  
   Yes 79 8 (10.1)  
Progesterone receptor 305   0.05
   Negative 80 11 (13.8)  
   Positive 225 15 (6.7)  
HER2 299   0.063
   Negative 179 20 (11.2)  
   Positive 120 6 (5.0)  
Androgen receptor 283   0.08
   Negative 90 11 (12.2)  
   Positive 193 12 (6.2)  
Cytokeratin 7/8 310   Not significant
   Negative 73 8 (11)  
   Positive 237 19 (8.0)  
Cytokeratin 18 269   Not significant
   Negative 46 1 (2.2)  
   Positive 223 21 (9.4)  
Cytokeratin 19 308   Not significant
   Negative 33 4 (12.1)  
   Positive 275 22 (8.0)  
Cytokeratin 5/6 306   Not significant
   Negative 261 24 (9.2)  
   Positive 45 2 (4.4)  
Cytokeratin 14 299   Not significant
   Negative 252 23 (9.1)  
   Positive 47 2 (4.3)  
Epidermal growth factor receptor 242   Not significant
   Negative 209 19 (9.1)  
   Positive 33 2 (6.1)  
Basal markers [27] 297   Not significant
   Negative 234 22 (9.4)  
   Positive 63 3 (4.8)